A top official at the Department of Health and Human Services wrote to Drug Enforcement Agency administrator Anne Milgram calling for marijuana to be reclassified as a Schedule III drug under the Controlled Substances Act, according to a letter dated Aug. 29 seen by Bloomberg News.
This would represent a critical shift from cannabis's status as a Schedule I substance, which deems marijuana as not having any medical benefits and places the plant in the same category as high-risk drugs like heroin.
Assistant Secretary for Health Rachel Levine, reports Bloomberg, said in the letter that her recommendation was based on a Food and Drug Administration review of marijuana’s classification, as promised following President Biden’s October pardon of federal offenses of simple possession. Around that time, Biden asked the HHS secretary and the U.S. Attorney General to undertake a review of how marijuana is scheduled under federal law.
Why It Matters
Marijuana’s current classification as a Schedule I substance is among the main reasons why cannabis companies remain deprived of banking access, medical research and interstate transport of products that are legal for medical purposes across dozens of US states. Despite this widespread acceptance of medical marijuana, only the FDA has the federal authority to approve drugs for medicinal use across the U.S.
Bloomberg noted that the HHS and DEA did not immediately respond to requests for comment.
Join us at the upcoming Benzinga Cannabis Capital Conference in Chicago on September 27 and 28 where you'll meet the CEOs, advocates and team members of cannabis companies and individuals directly affected by this news. And, who knows...maybe we'll be looking at an entirely different landscape for cannabis in terms of legalization, cannabis banking, cannabis investing and all that this booming industry deserves.
All information is available on bzcannabis.com Benzinga Cannabis Capital
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Click on the image for more info.
Cannabis rescheduling seems to be right around the corner
Want to understand what this means for the future of the industry?
Hear directly for top executives, investors and policymakers at the Benzinga Cannabis Capital Conference, coming to Chicago this Oct. 8-9.
Get your tickets now before prices surge by following this link.